söndag 26 januari 2014
Eli Lilly, Shame on you. Eli Lilly rewrites history on Darvon & Darvocet - they hide important data
During many years, there has not been one single word about Propoxyphene, Darvon or Darvocet when you look at the homepage of Eli Lilly. You may wonder why?
The reason is very simple: Eli Lilly wants people to FORGET all about their involvement in selling the painkilling substance Propoxyphene with the most popular brand names Darvon and Darvocet.
This substance has given the company profits in billions of dollars from the year the drug came out on the market, namely 1957 until 2002 when Eli Lilly sold the drug – brand names - to aaiPharma for $ 211.4 million. After a few years aaiPharma went bankruptcy and the rights to the drugs was bought by Xanodyne Pharmaceutical for $209,25 million.
It is highly remarkable that these two drug companies bought such a controversial drug. One can safely say that they have not done their home work. During the years 1998-2005 both our scientific articles and our doctoral dissertations were published. We strongly warned people of the drug's toxicity, which caused a large number of fatal poisonings. Money and greed control.
You can be sure that Eli Lilly know about our research and now was the time for them to sell and to get rid of the fatal drug and still earn some money.
After the banning of Propoxyphene (Darvon & Darvocet) November 19th 2010 the shareholders in Eli Lilly have some questions to ask, and therefore you are now able to read a few lines about Darvon & Darvocet and Propoxyphene on the homepage of the company. http://bit.ly/1isP5Kr
The shareholders want of course to know how deep Eli Lilly is involved in the Darvon/Darvocet disaster and how much the damages will be? In dollars and in reputation.
At these links you will find the two Annual Reports: http://bit.ly/1isP5Kr - Lilly Annual Report 2011 and 2012 you will find a few lines for each year about the world Darvon/Darvovet/Propoxyphene question:
2011 – Annual Report:
“Along with several other manufacturers, we have been named as a defendant in approximately 165 cases in the U.S. involving approximately 755 claimants related to the analgesic Darvon and related formulations of Propoxyphene”.
2012 - Annual Report:
“Along with several other manufacturers, we have been named as a defendant in approximately 125 cases in the U.S. involving approximately 1,890 claimants related to the analgesic Darvon and related formulations of propoxyphene”